Biomarin Pharmaceutical Stock News

SAN RAFAEL, Calif. , April 17, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, May 1, 2025, at 4:30 p.m.

The old idiom "blink, and you'll miss it" might be the best descriptor of the historic volatility we've witnessed on Wall Street over the trailing week, as of this writing on April 9.

BioMarin Pharmaceutical Inc.'s primary endpoint was met in the phase 3 Pegasus study, which used Palynziq for the treatment of adolescent patients ages 12 - 17 with phenylketonuria. The company is set to file regulatory applications to expand the label of Palynziq for phenylketonuria patients in both the U.S. and European territories in 2nd half of 2025. The global phenylketonuria market size i...

Company plans to submit for regulatory approval later this year SAN RAFAEL, Calif. , April 2, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Phase 3 PEGASUS trial evaluating PALYNZIQ ®  (pegvaliase-pqpz) met its primary efficacy endpoint, demonstrating a statistically significant lowering in blood Phe levels in adolescents aged 12-17 with phenylketonur...

Every so often, Wall Street sends a not-so-subtle reminder to investors that stocks can move in both directions.

New data also to be presented for PALYNZIQ® (pegvaliaise-pqpz), reinforcing its value in sustaining blood Phe level reduction and improving health-related quality of life for adults with phenylketonuria SAN RAFAEL, Calif. , March 20, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced positive new data from studies of VOXZOGO ® (vosoritide) in children with achondro...

SAN RAFAEL, Calif. , Feb. 25, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4, 2025, at 6:50 AM PT / 9:50 AM ET in Boston, MA.

SAN RAFAEL, Calif. , Feb. 24, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has appointed Timothy P.